14
5
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1484 |
Perindoprilat
Perindoprilate,培哚普利 |
RAAS; MRP; AChR | Endocrinology/Hormones; Immunology/Inflammation; Neuroscience |
Perindoprilat (Perindoprilate) 是一种血管紧张素转换酶抑制剂。 | |||
T13176 |
TNO155
Batoprotafib |
Phosphatase | Metabolism |
TNO155 是具有口服活性野生型SHP2的选择性变构抑制剂 (IC50= 0.011 µM)。它有研究 RTK 依赖性恶性肿瘤(尤其是晚期实体瘤)的潜力。 | |||
T4325 |
COTI-2
COTI 2,COTI2 |
Apoptosis; p53 | Apoptosis |
COTI-2是一种具有口服活性的低毒性抗癌药物,是 p53 突变体激活剂。它通过激活突变型 p53 和抑制PI3K/AKT/mTOR 途径发挥作用,通过 p53 依赖和非依赖机制在 HNSCC 中具有抗肿瘤活性。它诱导多种人肿瘤细胞凋亡,可将突变型 p53 转化为野生型构象。 | |||
T76890 |
Petosemtamab
MCLA 158 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Petosemtamab (MCLA 158) 是一种高效的抗 EGFR (Kd: 0.22 nM) 和抗 LGR5 (Kd: 0.86 nM) 单克隆抗体。Petosemtamab 促使 LGR5+ 癌细胞中的 EGFR 信号传导中断和受体分解。Petosemtamab 可用于头颈部鳞状细胞癌 (HNSCC)、转移性结直肠癌 (CRC) 等实体瘤的研究。 | |||
T76691 |
Monalizumab
|
IFNAR; Chk | Cell Cycle/Checkpoint; Immunology/Inflammation |
Monalizumab 是一种新型靶向自然杀伤细胞群 2A (NKG2A) 的免疫检查点抑制剂。Monalizumab 是一种人源化抗 NKG2A 的单克隆抗体,可促使 IFN-γ 产生,从而激活自然杀伤细胞功能。Monalizumab 具有抗肿瘤活性,可用于研究颈部鳞状细胞癌 (HNSCC)。 | |||
T10313 |
(Rac)-AMXT-1501 4HCl
|
Dopamine Receptor; Antibacterial | GPCR/G Protein; Microbiology/Virology; Neuroscience |
(Rac)-AMXT-1501 4HCl 是一种多胺转运抑制剂,抑制多胺转运与顺铂在 HNSCC 中协同作用。(Rac)-AMXT-1501 4HCl 具有潜在的抗菌活性,通过靶向鸟氨酸脱羧酶和多胺转运抑制神经母细胞瘤细胞增殖,抑制肺炎球菌的荚膜生物合成。 | |||
T16690 | Pyrazofurin | Others | Others |
Pyrazofurin is a pyrimidine nucleoside analogue, inhibits cell proliferation and DNA synthesis in cells by inhibiting UMP synthase. Pyrazofurin is a sensitive orotate-phosphoribosyltransferase inhibitor (IC50s between 0.06-0.37 µM in the cell lines Hep-2, | |||
T76918 | Barecetamab | ||
Barecetamab (ISU-104) 是一种人源话抗 ErbB3单克隆抗体。Barecetamab 可用于复发/转移性 (R/M) 头颈部鳞状细胞癌 (HNSCC) 的研究。 | |||
T9133L |
Caroverine
P 201-1 |
Others | Others |
Caroverine is a potential chemotherapeutical agent in HNSCC cell lines. | |||
T62790 |
JH-XIV-68-3
|
Others | Others |
JH-XIV-68-3 是一种选择性的 DYRK1A/B 大环抑制剂。JH-XIV-68-3 在生化和细胞测定中能够选择性作用于 DYRK1A 和近亲 DYRK1B。JH-XIV-68-3 在头颈部鳞状细胞癌 (HNSCC) 细胞系中具有抗肿瘤作用。 | |||
T72776 |
NR2F1 agonist 1
|
Others | Others |
NR2F1 agonist 1 是一种核受体 NR2F1激动剂,可特异性激活恶性细胞的休眠程序。NR2F1 agonist 1 上调 NR2F1 和调节休眠的下游靶基因。NR2F1 agonist 1 通过 NR2F1 激活在头颈部鳞状细胞癌 (HNSCC) 中诱导神经嵴样生长抑制。NR2F1 agonist 1 在小鼠原发肿瘤模型中抑制肿瘤生长。 | |||
T82188 |
HN-1
|
||
HN-1为一种12-mer多肽,在头颈部鳞状细胞癌(HNSCC)细胞上展现特异性活性。作为肿瘤特异性肽,HN-1可渗透肿瘤组织,并在细胞膜上转移活性分子。 | |||
T63050 |
JH-XVII-10
|
Others | Others |
JH-XVII-10 是一种具有选择性的、口服具有活力的、有效的 DYRK1A (IC50: 3 nM) 和 DYRK1B (IC50: 5 nM) 抑制剂。JH-XVII-10 在颈部鳞状细胞癌 (HNSCC) 细胞系中表现出抗肿瘤效果。 | |||
T68663 |
GPI-15427
|
Others | Others |
GPI-15427 is a potent PARP-1 inhibitor capable of crossing the blood-brain barrier, which can significantly increased the antitumor activity of the methylating agent TMZ against malignant melanoma, glioblastoma multiforme, or lymphoma growing at the CNS site. GPI-15427 acts as a potent inhibitor of the enzyme, being capable of inhibiting the activity of purified PARP-1 at nanomolar concentrations. GPI-15427 induced significant sensitization to radiotherapy, representing a promising new treatment... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00782 |
PLAU/uPA Protein, Mouse, Recombinant (His & Avi)
PLAU,UPA,BDPLT5,ATF,u-PA,QPD,Urokinase,URK |
Mouse | HEK293 Cells |
Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. PLAU/uPA Protein, Mouse, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 49.00 kDa and the accession number is P06869. | |||
TMPK-00274 |
PLAU/uPA Protein (active form), Human, Recombinant (His & Avi), Biotinylated
QPD,Urokinase,BDPLT5,UPA,ATF,URK,u-PA,PLAU |
Human | HEK293 Cells |
Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. PLAU/uPA Protein (active form), Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 49.3 kDa and the accession number is P0074... | |||
TMPK-00539 |
PLAU/uPA Protein (active form), Cynomolgus, Recombinant (His)
URK,ATF,UPA,u-PA,Urokinase,QPD,PLAU,BDPLT5 |
Cynomolgus | HEK293 Cells |
Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. PLAU/uPA Protein (active form), Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 47.23 kDa and the accession number is A0A2K5WND1. | |||
TMPK-00783 |
PLAU/uPA Protein, Mouse, Recombinant (His & Avi), Biotinylated
ATF,URK,Urokinase,PLAU,u-PA,UPA,QPD,BDPLT5 |
Mouse | HEK293 Cells |
Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC. PLAU/uPA Protein, Mouse, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 49.00 kDa and the accession number is P06869. | |||
TMPY-03748 |
BCL2L12 Protein, Human, Recombinant (GST)
BCL2-like 12 (proline rich) |
Human | E. coli |
BCL2-like 12 (BCL2L12 ) is a new member of the apoptosis-related BCL2 gene family, members of which are implicated in various malignancies. The mRNA expression of BCL2L12 may constitute a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. BCL2L12 is a recently identified gene belonging to the BCL2 family, members of which are implicated in hematologic malignancies, including chronic lymphocytic leukemia (CLL). BCL2L12 can be considered as a new independent prog... |